157 Infectious Disease CRO and CDMO vendors

What kind of CRO work does an Infectious Disease program need?

Infectious disease is one of the few areas where your drug has a living, mutating opponent, and that shapes almost every piece of the outsourcing scope. Discovery work starts with in vitro potency against the pathogen itself: MIC and MBC for antibacterials, plaque-reduction and yield-reduction assays for antivirals, and EC50 panels run across a spread of clinical isolates rather than a single lab strain. The single most useful question to ask a vendor early is which pathogens they actually hold, under what biosafety level, and whether their strain panel reflects current resistance patterns or a collection that stopped being representative years ago.

From there the work moves into the parts most sponsors cannot run themselves. Resistance characterization (serial passage to select resistant mutants, frequency-of-resistance measurement, whole-genome sequencing to map the mechanism) tells you how durable your molecule is. Time-kill kinetics and the hollow-fiber infection model bridge potency to dosing by showing whether the drug is concentration- or time-dependent. Then come the in vivo efficacy models: neutropenic mouse thigh and lung infection for bacteria, sepsis and bacteremia models, and respiratory or systemic challenge models for viral and fungal programs. A meaningful share of this lives at BSL-3 (think influenza, TB, certain BSL-3 select agents), and not every CRO is built or licensed for it.

Two things separate infectious disease from most other therapeutic areas, and a good vendor will raise them before you do. PK/PD integration matters more here than almost anywhere else: regulators expect a defined PK/PD index and target (fAUC/MIC, %T>MIC, or Cmax/MIC) tied back to the animal models, so the group running your efficacy studies should speak that language. And on the biologics and vaccine side, the CDMO scope is real, with cell-line and viral-vector manufacturing, adjuvant formulation, potency and neutralizing-antibody assays, and sterile fill-finish, all under the cold-chain and sterility constraints these products demand.

How do you choose a CRO for Infectious Disease?

The deciding factor in infectious disease is rarely price, it is whether the vendor genuinely has the pathogen, the biosafety containment, and the validated model your specific program needs. A CRO with a beautiful BSL-2 bacterial efficacy operation is the wrong choice for a respiratory virus that demands BSL-3 challenge work, and a strain collection that does not include current resistant isolates will flatter a weak molecule. Scope two or three vendors against the same written protocol and work through the checklist below before you commit.

• Therapeutic-area and pathogen experience: confirm they have run programs against your specific organism class (Gram-negative, mycobacteria, respiratory virus, fungus) and ask for relevant, recent work, not a generic capability slide.
• Strain panels and patient relevance: check that their isolate collection reflects current resistance, including reference and clinical strains and the relevant ATCC or CLSI panels, plus any drug-resistant lineages your indication targets.
• Biosafety containment and licensing: verify the actual biosafety level (BSL-2 vs BSL-3) for both lab and animal work, select-agent registration where it applies, and that containment is licensed for your pathogen rather than aspirational.
• Regulatory and quality track record: ask whether IND-enabling studies run under GLP, how their MIC and susceptibility methods map to CLSI or EUCAST breakpoints, and whether their PK/PD packages have supported FDA or EMA submissions.
• Data quality and method validation: look for documented assay validation, QC controls on every plate, isolate provenance and authentication, and raw data you can trace, since an unvalidated potency assay poisons every decision downstream.
• PK/PD and translational depth: confirm they can connect in vitro potency, time-kill, and hollow-fiber data to a defined PK/PD index and animal efficacy, which is what regulators expect for an anti-infective dose rationale.
• Capacity and realistic lead time: BSL-3 suites and challenge-model slots are genuinely scarce, so confirm current queue and a realistic start date rather than assuming availability.